MCK241004P475000
- 0.05
- -0.50-90.91%
McKesson Newsroom
Argus Research Maintains McKesson(MCK.US) With Buy Rating, Announces Target Price $570
Argus Adjusts Price Target on McKesson to $570 From $640
Deutsche Bank Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $579
Buy Rating Affirmed: McKesson's Long-term Growth Strategy Balances Short-term Earnings Concerns
Baird Downgrades McKesson(MCK.US) to Hold Rating, Cuts Target Price to $531
McKesson: Operational and Strategic Challenges Prompt Hold Rating
McKesson Is Maintained at Equal-Weight by Wells Fargo
McKesson Analyst Ratings
Deutsche Bank Trims Price Target on McKesson to $623 From $631
Leerink Partners Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $665
Michael Cherny Reaffirms Buy Rating on McKesson Amid Temporary Setbacks and Long-Term Growth Prospects
Wells Fargo Maintains McKesson(MCK.US) With Hold Rating, Cuts Target Price to $535
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), McKesson (MCK) and Neurocrine (NBIX)
McKesson Analyst Ratings
Jefferies Adjusts Price Target on McKesson to $607 From $630
Citi Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $630
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616
A Quick Look at Today's Ratings for McKesson(MCK.US), With a Forecast Between $576 to $665
Wells Fargo Gives a Hold Rating to McKesson (MCK)
Strategic Divestitures Bolster McKesson's Focus on High-Growth Oncology Market: Maintaining Buy Rating